<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CALCIUM GLUCEPTATE</span><br/>(gloo-sep'tate)<br/><span class="topboxtradename">Calcium Glucoheptonate, </span><span class="topboxtradename">Glucalcium, </span><span class="topboxtradename">Calcitrans<br/></span><b>Classifications:</b> <span class="classification">fluid and electrolytic balance agent</span>; <span class="classification">replacement solution</span><br/><b>Prototype: </b>Calcium gluconate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.1 g/5 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Calcium is an essential element for regulating the excitation threshold of nerves and muscles, blood clotting mechanisms,
         cardiac function, maintenance of renal function, and body skeleton and teeth. Also plays a role in regulating neurotransmitters
         and hormones, and functional integrity of cell membranes and capillaries. Calcium gluceptate acts like digitalis on the heart,
         increasing cardiac muscle tone and force of systolic contractions (positive inotropic effect).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Preferred for use when IM administration is required as in neonatal tetany. Rapidly and effectively restores serum calcium
         levels in acute hypocalcemia of various origins and an effective cardiac stabilizer under conditions of hyperkalemia or resuscitation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To correct hypocalcemia and following each 100 mL of exchange transfusion in newborns.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Ventricular fibrillation, hypercalcemia, digitalis toxicity, injection into myocardium or other tissue; pregnancy (category
         C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Digitalized patients; sarcoidosis, renal insufficiency, history of renal stone formation; cor pulmonale, respiratory acidosis,
         respiratory failure; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p>
<b>All doses are in terms of <i>elemental calcium:</i> 1 g calcium gluceptate = 82 mg (4.1 mEq) elemental calcium</b>
</p><span class="indicationtitle">Hypocalcemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1.14.4 g/d <span class="rdroute">IM</span> 0.51.1 g.d. in 25 mL (220 mg/mL)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 200500 mg/kg/d divided q6h <span class="rdroute">IM</span> 0.51.1 g/d in 25 mL (220 mg/mL)<br/><br/><span class="indicationtitle">Exchange Transfusions with Citrated Blood</span><br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 0.5 mL after each 100 mL of blood exchanged<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>IM injection may produce mild local reactions. Generally, this route is used only in adults when IV administration is not
            feasible.
         </li>
<li>Recommended IM site for adults is the upper outer quadrant of the buttock and in infants (if prescribed) the midlateral thigh.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May be given undiluted. Solution should be warmed to body temperature before administration.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give at a rate not to exceed 1 mL/min or more slowly if irritation develops. Avoid rapid administration.  
               </p>
<ul>
<li>Patient may complain of a transient tingling sensation and metallic taste following IV administration.</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Tingling sensation. With rapid IV, sensations of heat waves (peripheral vasodilation), fainting. <span class="typehead">CV:</span> (With rapid infusion) hypotension, bradycardia, cardiac arrhythmias, <span class="speceff-life">cardiac arrest</span>. <span class="typehead">Skin:</span> Pain and burning at IV site, severe venous thrombosis, necrosis and sloughing (with extravasation). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance inotropic and toxic effects of <b>digoxin;</b> antagonizes the effects of <b>verapamil</b> and possibly other <span class="classification">calcium channel blockers</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 23 h IV; 14 h IM. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Elimination:</span> Primarily excreted in feces; small amounts excreted in urine, pancreatic juice, saliva, and breast milk. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p>See calcium gluconate for additional <b>NURSING IMPLICATIONS</b>.
      </p>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>